button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 2 statistically conclusive-38%statistically conclusive-54%-
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 certainty unassessable-32% certainty unassessable-24%-
relatlimab plus nivolumab vs. nivolumab alone 1 - certainty unassessable-23%-

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 certainty unassessable+44% certainty unassessable-57%-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 - certainty unassessablestatistically conclusive-55%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons